It can be taken with water, with or without food. To aid compliance, patients should be encouraged to take their dose at the same time every day.

Treatment with LIXIANA® in patients with NVAF should be continued long term. The duration of treatment for VTE and prevention of recurrent VTE should be individualised after assessment of the treatment benefit against the risk for bleeding. Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE.

Dose reduction

A dose of 30 mg once daily is required for certain patients who fall into one or more of the following sub-groups.
These are:

In this case, patients should take one 30 mg tablet at the same time every day, with or without food.

Initiating treatment

For the treatment of VTE, patients should receive an initial course of heparin for at least 5 days prior to treatment with LIXIANA®. This is not required for the initiation of LIXIANA® in patients with NVAF for the prevention of stroke and systemic embolism.

Information on switching patients to LIXIANA® from other treatments can be found here.

Missed dose

If a patient misses a dose of LIXIANA® he/she should take it immediately and then continue the following day with the once-daily intake as recommended.

The patient should not take double the prescribed dose on the same day to make up for a missed dose.

Reference (click to access full publication)